Amgen Inc. (AMGN): Business Model Canvas [June-2026 Updated]

This ready-made Business Model Canvas of Amgen Inc. gives you a practical, research-based view of how the company creates, delivers, and captures value through oncology, rare disease, bone, cardiovascular, and immunology products, biosimilars, and international sales. You'll see the core drivers behind its business model, including 273 clinical studies, heavy R&D, biologics manufacturing, regulatory approvals in the US and EU, physician and specialist relationships, hospitals and specialty pharmacies as channels, strong cash flow, and key partnerships across trial sites, supply-chain partners, regulators, and a 2026 sports partnership.

Amgen Inc. - Canvas Business Model: Key Partnerships

$28.190 billion in 2023 revenue and $4.511 billion in 2023 R&D spending show the scale behind Amgen Inc.'s partner network.

• $28.190 billion revenue
• $4.511 billion R&D
• 0 public Amgen-OpenAI enterprise contract disclosure
• 0 public Amgen-FIFA World Cup 2026 sponsorship disclosure
• 0 public named external manufacturing partner count disclosure
• 0 public company-level trial site count disclosure

European Commission

European Medicines Agency

U.S. Food and Drug Administration

Pharmaceuticals and Medical Devices Agency

Medicines and Healthcare products Regulatory Agency

Amgen Inc. - Canvas Business Model: Key Activities

273 studies, 28,000 employees, 100+ countries, and $33.4B in 2024 revenue define the activity base behind Amgen Inc.'s business model.

Drug discovery and R&D: 273 studies sit at the center of the development engine.

• 273 studies.
• 28,000 employees.
• 2024 revenue: $33.4B.

Clinical trials across 273 studies: 273 studies.

• 273 studies.
• 100+ countries.

Global regulatory filings and approvals: 100+ countries.

• 100+ countries.
• 273 studies.

Biologics manufacturing and scale-up: 28,000 employees.

• 28,000 employees.
• 2024 revenue: $33.4B.

Commercialization and market access: $33.4B revenue and 100+ countries.

• $33.4B revenue in 2024.
• 100+ countries.
• 28,000 employees.

Amgen Inc. - Canvas Business Model: Key Resources

Amgen Inc.'s key resources are built around a $33.4B revenue base, $4.8B of R&D spending, a $27.8B acquisition, and about 28,000 employees. Those numbers show a capital-intensive biotech model that depends on approved medicines, late-stage development, global production, and financing capacity.

Branded biologic portfolio

The portfolio is the core resource because it turns approved medicines into recurring sales. Amgen Inc. reported $33.4B in revenue in 2024, so the company's business model still depends on products already in the market rather than only on future approvals. In a biologics business, this matters because each approved product can support years of manufacturing, pricing, and lifecycle management. For academic writing, this is the clearest example of how intellectual property becomes cash flow.

Late-stage pipeline

Amgen Inc. spent $4.8B on research and development in 2024. That spending is the clearest public measure of its late-stage pipeline resource, because it covers clinical development, regulatory work, and data generation. The pipeline matters strategically because it replaces revenue when mature products face loss of exclusivity, pricing pressure, or slower growth. A company with this level of R&D spending can keep more programs moving at the same time than a smaller biotech can.

AI and data science capabilities

Amgen Inc. does not report a separate AI budget line, so the public number that best captures this resource is still the $4.8B R&D base. AI and data science sit inside that spending and support target selection, trial design, and manufacturing analytics. This matters because better data use can reduce failed experiments, improve program selection, and help the company direct capital toward the most promising assets.

Global manufacturing network

The manufacturing resource is a regulated production system rather than a single plant. Amgen Inc. operates across the United States, Ireland, Puerto Rico, and Singapore. That geographic spread matters because biologics are harder to make than small-molecule drugs, and supply disruptions can hurt revenue fast. The network also supports quality control, redundancy, and scaling when a product grows quickly after launch.

• 4 major geographies for manufacturing and supply support.
• $33.4B in 2024 revenue gives production assets a large commercial base.
• $4.8B in R&D keeps the manufacturing pipeline linked to future launches.

Strong cash flow and balance sheet

The balance sheet became more important after the $27.8B Horizon Therapeutics acquisition. Large cash generation matters because it funds R&D, supports capital spending, and helps service debt without depending on equity markets. For a biologics company, this is a key resource because product development and plant investment both need long funding horizons. Revenue of $33.4B gives Amgen Inc. scale, while the acquisition size shows how much financial capacity the company needs to keep expanding.

About 28,000 employees support these resources across research, manufacturing, quality, regulatory, and commercial functions. That headcount matters because it shows Amgen Inc. is operating at the scale of a large pharmaceutical company, not a small research-stage biotech.

Amgen Inc. - Canvas Business Model: Value Propositions

Amgen's 2024 revenue was $33.424 billion.

Innovative therapies in oncology and rare disease

Imdelltra received U.S. FDA approval in 2024 for extensive-stage small cell lung cancer after platinum-based chemotherapy. The pivotal data showed a 40% confirmed overall response rate and a 9.7-month median duration of response.

Blincyto has a measurable survival profile in B-cell precursor acute lymphoblastic leukemia. In the TOWER study, median overall survival was 7.7 months versus 4.0 months, and complete remission or complete remission with partial hematologic recovery was 34% versus 16%.

Amgen completed the Horizon Therapeutics acquisition in 2023 for $27.8 billion. Tepezza is given as 8 infusions over 24 weeks. Krystexxa is dosed every 2 weeks.

Leading bone, cardiovascular, and immunology brands

Convenient dosing innovations

• Prolia: 1 dose every 6 months
• Evenity: 12 monthly doses
• Repatha: 140 mg every 2 weeks or 420 mg monthly
• Aimovig: 70 mg or 140 mg monthly
• Tezspire: 210 mg every 4 weeks
• Neulasta Onpro: drug delivery begins about 27 hours after application

Global access through new approvals

Imdelltra added a 2024 U.S. approval to the portfolio. Horizon Therapeutics added a 2023 rare-disease platform for $27.8 billion.

Tepezza uses an 8-infusion regimen over 24 weeks. Krystexxa is dosed every 2 weeks.

Biosimilar and life-cycle management expertise

• Amjevita launched in the U.S. in 2023 as the first adalimumab biosimilar to reach the market there
• Neulasta Onpro combines a 6 mg dose with automated delivery about 27 hours after application
• Enbrel remains a 50 mg weekly regimen
• Prolia remains a 6-month regimen
• Repatha remains a 2-week or monthly regimen
• Evenity remains a 12-month regimen

Amgen Inc. - Canvas Business Model: Customer Relationships

Amgen's customer relationships are built around specialist prescribers, patient access support, safety follow-up, and research partnerships. The company reported $28.2 billion in net sales in 2023 and sells products in more than 100 countries, so relationship quality affects both prescription volume and long-term treatment persistence.

Physician and specialist engagement is the core relationship layer. Amgen sells biologic and specialty medicines that are prescribed mainly by specialists, not by general consumer demand. That makes scientific credibility, peer review, and clinical data more important than mass advertising. In practice, the relationship is built through medical education, field-based account support, and ongoing dialogue about patient selection, dosing, administration, and monitoring.

• Specialist relationships influence whether a therapy is started, continued, or switched.
• Long-term treatment areas make repeat interaction more valuable than one-time selling.
• Clinical familiarity helps prescribers manage safety, adherence, and follow-up.

Patient access support via AmgenNow is the main patient-facing relationship channel. Specialty medicines often face insurance review, step edits, and out-of-pocket cost pressure, so access support is part of the product experience, not an extra service. AmgenNow helps patients and office staff move from prescription to approved treatment, which matters most when therapy cannot start until coverage is confirmed.

• Benefits verification helps offices see what the insurer will pay before treatment starts.
• Prior authorization support helps reduce administrative delays.
• Financial assistance can lower abandonment when patient cost exposure is high.

Medical affairs and market access teams keep the relationship both scientific and reimbursable. Medical affairs speaks to evidence, clinical use, and disease education. Market access speaks to payer value, formulary placement, and budget impact. This dual structure matters because a medicine can have clinical demand but still fail commercially if coverage is weak or reimbursement is slow.

• Medical affairs supports evidence-based dialogue with clinicians and institutions.
• Market access supports payer reviews and coverage decisions.
• For a company with $28.2 billion in 2023 net sales, reimbursement quality directly affects realized revenue.

Ongoing post-launch safety monitoring is part of the customer relationship because specialty biologics are often used for years. Amgen must keep collecting adverse-event reports, monitor safety signals, and meet post-marketing obligations where required. That process matters to physicians because it tells them whether real-world use matches the clinical trial profile.

• Safety monitoring supports physician confidence after approval.
• It helps regulators and prescribers evaluate long-term use.
• It reduces the risk of trust loss from unmanaged safety concerns.

Research collaboration with trial centers starts before launch and continues after launch. Amgen works with academic centers and clinical investigators to run studies, generate evidence, and refine how therapies are used in practice. These relationships matter because the same centers that run trials often influence guidelines, specialist opinion, and future prescribing patterns.

• Trial-center partnerships support patient recruitment and protocol execution.
• Investigators become long-term scientific partners for future studies.
• Clinical evidence from these centers helps support physician and payer confidence.

Amgen Inc. - Canvas Business Model: Channels

Amgen Inc. uses 4 channel layers: hospitals and specialty clinics, specialty pharmacies and distributors, a direct commercial sales force, and U.S./EU regulatory access. The channel design is built around fixed-dose biologics such as 60 mg every 6 months, 120 mg every 4 weeks, 210 mg every 4 weeks, and 28-day infusion cycles.

Hospitals and specialty clinics handle the products that need administration by a healthcare professional, infusion monitoring, or step-up dosing. Blincyto uses continuous intravenous infusion over 28 days; Xgeva is given as 120 mg every 4 weeks; Evenity is 210 mg monthly for 12 months; Prolia is 60 mg every 6 months; Imdelltra uses a step-up dose of 1 mg followed by 10 mg every 2 weeks.

• Blincyto: continuous IV infusion over 28 days
• Xgeva: 120 mg every 4 weeks
• Evenity: 210 mg every 4 weeks for 12 months
• Prolia: 60 mg every 6 months
• Imdelltra: 1 mg step-up dose, then 10 mg every 2 weeks

Specialty pharmacies and distributors carry the products that move through the pharmacy benefit and need cold-chain or refill coordination. Repatha is dispensed as 140 mg every 2 weeks or 420 mg monthly; Otezla is dosed at 30 mg twice daily after titration; Tezspire is 210 mg every 4 weeks. For biologics in this channel, shipment conditions commonly run at 2°C to 8°C.

• Repatha: 140 mg every 2 weeks or 420 mg monthly
• Otezla: 30 mg twice daily after titration
• Tezspire: 210 mg every 4 weeks
• Cold-chain range: 2°C to 8°C

The direct commercial sales force is organized around specialty call points rather than retail volume. The channel footprint spans 50 U.S. states, 27 EU member states, and more than 100 countries, which matches Amgen Inc.'s mix of oncology, bone health, cardiovascular, inflammation, and rare disease products.

Amgen Inc.'s U.S. and EU regulatory channel is a launch gate, not just a formality. One FDA approval opens the U.S. market; one centralized EU authorization can open 27 member states. Imdelltra received FDA accelerated approval on 2024-05-16; Tezspire, Repatha, Prolia, Xgeva, Evenity, and Blincyto all depend on this same approval-to-access path before field sales and pharmacy fulfillment can scale.

Digital and AI-enabled access platforms sit between the prescriber, the payer, and the dispensing channel. The core workflow is benefits verification, prior authorization, copay support, and refill tracking across the 2 main payment paths: medical benefit and pharmacy benefit.

• 2 payment paths: medical benefit and pharmacy benefit
• Benefits verification
• Prior authorization
• Copay support
• Refill tracking

Amgen Inc. - Canvas Business Model: Customer Segments

2,001,140 new U.S. cancer cases, 611,720 cancer deaths, 10 million U.S. osteoporosis cases, 44 million U.S. adults with low bone mass, 40.3% U.S. adult obesity prevalence, and a rare-disease cutoff of fewer than 200,000 U.S. patients per condition define the main customer pools for Amgen Inc. in late 2025.

Cancer patients and oncologists

• 2,001,140 U.S. new cancer cases in 2024
• 611,720 U.S. cancer deaths in 2024
• 2 large demand signals: incidence and mortality

Rare disease patients and specialists

• Fewer than 200,000 U.S. patients per rare disease
• 1 to 10 per 100,000 prevalence range for neuromyelitis optica spectrum disorder
• 200,000 is the U.S. rare-disease cutoff

Osteoporosis and bone disease patients

• 10 million U.S. adults with osteoporosis
• 44 million U.S. adults with low bone mass
• 1 in 2 women and 1 in 4 men over 50 will break a bone because of osteoporosis

Cardiovascular and obesity treatment markets

• 40.3% U.S. adult obesity prevalence
• 9.4% U.S. adult severe obesity prevalence
• 1 in 250 people with familial hypercholesterolemia

Payers, providers, and health systems

• More than 65 million Medicare beneficiaries
• More than 70 million Medicaid and CHIP enrollees
• 200,000 patient threshold for rare-disease coverage decisions

Amgen Inc. - Canvas Business Model: Cost Structure

$33.4 billion revenue, $9.3 billion cost of sales, $5.4 billion research and development, $5.9 billion selling, general and administrative, $20.6 billion operating costs, $12.8 billion operating income, $27.8 billion Horizon acquisition purchase price.

• $5.4 billion research and development
• $9.3 billion cost of sales
• $5.9 billion selling, general and administrative
• $27.8 billion acquisition purchase price

Amgen Inc. - Canvas Business Model: Revenue Streams

$33,424 million total revenue, $32,835 million product sales, $589 million other revenue, 98.2% product-sales mix, 1.8% other-revenue mix.

Product sales from key brands

• Prolia
• Enbrel
• Repatha
• Otezla
• Xgeva
• Evenity
• Kyprolis
• Nplate
• BLINCYTO
• TEZSPIRE
• Mvasi
• Kanjinti
• Vectibix
• Parsabiv
• Lumakras/Lumykras

Oncology and rare disease therapies

Cardiovascular and bone health products

• Cardiovascular: Repatha
• Bone health: Prolia, Xgeva, Evenity

Biosimilar sales

International product sales

$32,835 million product sales base includes non-U.S. sales for Repatha, Prolia, Xgeva, TEZSPIRE, and the biosimilar portfolio.